The NK1 receptor antagonist aprepitant attenuates NK1 agonist‐induced scratching behaviour in the gerbil after intra‐dermal, topical or oral administration

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0625|24|4|312-314

ISSN： 0906-6705

Source： EXPERIMENTAL DERMATOLOGY (ELECTRONIC), Vol.24, Iss.4, 2015-04, pp. : 312-314

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 3, 2017-11 ,pp. : 193-201

Bentham Science Publishers

Access to resources Recommend Favorite

Equivalent Dynamic Human Brain NK1‐Receptor Occupancy Following Single‐Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. : 243-250

John Wiley & Sons Inc

Access to resources Recommend Favorite

Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone‐induced atopic dermatitis model

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 10, 2015-10 ,pp. : e401-e408

John Wiley & Sons Inc

Access to resources Recommend Favorite

Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone‐induced atopic dermatitis model

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 11-9059, Iss. 10, 2015-10 ,pp. : e401-e408

John Wiley & Sons Inc

Access to resources Recommend Favorite

A substance P receptor (NK 1 ) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II

By Kingery W.S.   Davies M.F.   Clark J.D.  

Pain, Vol. 104, Iss. 1, 2003-07 ,pp. : 75-84

Elsevier

Access to resources Recommend Favorite